ChromaDex (NAGE) Price to Earnings Ratio

Chromadex Corp - graphic logo of issuer NAGE

Minimal geopolitical influence creates a stable backdrop for Chromadex Corp (NAGE). Resilience is driven by B2B supplies of the Niagen component, which guarantee regular orders and high margins. The company's monthly P/E dynamics visualize the value of future earnings, where the value of 16.40 reflects the metric's balance. Innovations in cellular regeneration and DNA repair to slow aging establish the foundation for growth.

ChromaDex Corp (NAGE) - P/E Multiple from 03/20/2025 to 11/12/2026

Analytical breakdowns for Chromadex Corp

- price and consensus price forecast:
Stock Price Niagen|NAGE - Price Target Chart
- market capitalization details:
Market Value ChromaDex Corp.|NAGE - Real Price to Acquire Entire Company
- book capitalization information:
Accounting Value of a Share ChromaDex|NAGE - Book Capitalization|Market Capitalization to Book Value niagenbioscience.com|NAGE - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio Chromadex Corp|NAGE - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient niagenbioscience.com|NAGE - Company Total Debt|Debt to Book Capital ChromaDex Corp.|NAGE - Company Long-Term Debt|Company Short-Term Loans and Borrowings ChromaDex|Quick Ratio niagenbioscience.com
- earnings and valuation multiples indicators:
NAGE - Company Net Income|Future Profit Chromadex Corp|NAGE - P/E Multiple|Projected Price to Earnings Ratio ChromaDex Corp|NAGE - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation ChromaDex Corp.|NAGE - Operating profit before deduction of amortization|Earnings per share for the last four quarters ChromaDex|NAGE - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months niagenbioscience.com|NAGE - Earnings growth in current year|Expected earnings per share growth for next year Chromadex Corp
General company analysis:ChromaDex Corp., NAGE
Product sample of niagenbioscience.com

Investors determine the potential of Chromadex Corp (NAGE) through the price-to-earnings ratio, which measures the cost of one dollar of current earnings and reflects market expectations for future growth rates. By analyzing the company's calculated P/E, the strategist assesses whether the premium for the expansion of biohacking products in retail is justified, separating the business's fundamental value from speculative price inflation.

Analysis of competing companies

P/E Multiple intuitive.com|Price to Earnings Ratio Danaher (DHR)|Price to Earnings Ratio BDX (BD)|STERIS Corporation - Price to Earnings Ratio|Company Value to Net Income WST|Baxter International - P/E Multiple|Business Payback Period masimo.com MASI|Stevanato Group (STVN) - Price to Earnings Ratio|Price to Earnings Multiple TFX|Price to Earnings Ratio Merit Medical Systems Inc|Nobel Biocare (NVST) - Business Payback Period|Price to Earnings Ratio ICUI (ICU Medical, Inc.)|Market Price to Net Income Ratio XRAY|Price to Earnings Ratio LeMaitre Vascular LMAT|Company Value to Net Income ATRC|STAA: Price to Earnings Ratio|ZIMV - P/E Multiple|AngioDynamics, Inc. (ANGO) - Price to Earnings Ratio|Price to Earnings Ratio cerus.com|TKNO (Teknova) - P/E Multiple|Market Cap to Earnings Monogram Technologies Inc. MGRM|Price to Earnings Ratio Sharps Technology, Inc. (STSS)|infusystem.com - Price to Earnings Multiple|Utah Medical Products - Price to Earnings Ratio|Market Price to Net Income Ratio KRMD (KORU Medical Systems, Inc.)|NYXH - Price to Earnings Ratio|Business Payback Period Microbot Medical, Inc. MBOT|PDEX: P/E Multiple|Price to Earnings Ratio Zentek Corp|ELUT (Elutia Inc.) - P/E Multiple|MLSS: Company Value to Net Income|Price to Earnings Ratio NEXGEL (NXGL)|RVP (retractable.com) - Company Value to Net Income|Price to Earnings Ratio Harvard Bioscience HBIO|Femasys Corporation (FEMY) - Market Cap to Earnings|MHUA - Price to Earnings Ratio|Predictive Oncology (POAI) - Price to Earnings Ratio|CJMB: P/E Multiple|Atrion Corp. (ATRI) - P/E Multiple|NURO (NeuroMetrix Corp) - P/E Multiple